The SPRINT data suggest a cardiovascular benefit of intensive blood pressure (BP) lowering in high-risk individuals. The BP measurement protocol, however, likely resulted in lower BP values than would normally be obtained in the clinic. Intensive BP targets might not be as safe if routine BP measurements are used.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Blood pressure trajectory modeling in childhood: birth-cohort study
Clinical Hypertension Open Access 15 January 2020
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Wright, J. T. Jr et al. A randomized trial of intensive versus standard blood-pressure control. N. Engl. J. Med. 373, 2103–2116 (2015).
Agarwal, R., Pappas, M. K. & Sinha, A. D. Masked uncontrolled hypertension in CKD. J. Am. Soc. Nephrol. http://dx.doi.org/10.1681/ASN.2015030243 (2015).
Sheikh, S., Sinha, A. D. & Agarwal, R. Home blood pressure monitoring: how good a predictor of long-term risk? Curr. Hypertens. Rep. 13, 192–199 (2011).
McManus, R. J. et al. Telemonitoring and self-management in the control of hypertension (TASMINH2): a randomised controlled trial. Lancet 376, 163–172 (2010).
Agarwal, R., Bills, J. E., Hecht, T. J. & Light, R. P. Role of home blood pressure monitoring in overcoming therapeutic inertia and improving hypertension control: a systematic review and meta-analysis. Hypertension 57, 29–38 (2011).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
R.A. has consulted for pharmaceutical companies that make antihypertensive drugs: Abbvie, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Johnson and Johnson, Merck, Novartis and Takeda. He serves on the steering committees of clinical trials funded by Bayer, Celgene, Johnson and Johnson, Opko and Relypsa.
Rights and permissions
About this article
Cite this article
Agarwal, R. Rest before blood pressure measurement: a lesson from SPRINT. Nat Rev Nephrol 12, 127–128 (2016). https://doi.org/10.1038/nrneph.2016.2
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneph.2016.2
This article is cited by
-
Blood pressure trajectory modeling in childhood: birth-cohort study
Clinical Hypertension (2020)